Beyond UBE3A: New Conversations About Genotype, Variants, and Future Treatments
At INSYNC-AS 2026, researchers came together to examine how genes beyond UBE3A and differences within UBE3A itself may shape Angelman syndrome and future therapeutic development. Why can Angelman syndrome (AS) look different from one person to another, even when the diagnosis is the same? And could understanding those differences help researchers develop better treatment approaches […]
Non-viral delivery gene editing takes an important step forward for Angelman syndrome
A FAST-funded study unveils STEP-RNP, a non-viral gene editing platform showing improved motor, cognitive function in AS mice—an early but promising step toward treating Angelman syndrome.
Using Vocalization Testing to Improve Detection of Treatment Effects in Angelman Syndrome Models
New research adds ultrasonic vocalization testing to Angelman syndrome mouse studies, offering a more sensitive way to detect communication-related changes and evaluate future treatments.
Celebrating Dr. David Segal: A Leader in Science and a Champion for Angelman Syndrome Research
FAST congratulates longtime research partner Dr. David J. Segal on his appointment as Chair of Biochemistry and Molecular Medicine at UC Davis, a milestone for the AS research community.
FAST × ASA Angelman Syndrome Clinical Trials Webinar: Europe/UK Sites, Eligibility, and How to Join Trials
FAST and ASA co-hosted a UK/Europe session with Ultragenyx and Ionis, giving families clear updates on ASO trial programs ASPIRE and REVEAL, tailored to UK/EU time zones.
Reading the brain’s signals to speed better treatments for Angelman syndrome
FAST-funded research identifies peak alpha frequency, an EEG biomarker that could reveal early brain responses to Angelman syndrome treatment before day-to-day changes appear.
Inside INSYNC-AS 2025: Progress, Partnership, and Possibilities for Angelman Syndrome
The 5th Annual INSYNC-AS Meeting brought together top researchers to tackle brain-targeted drug delivery, sharing breakthroughs in blood-brain barrier crossing for Angelman syndrome therapies.
FAST-funded researcher highlights the involvement of UBE3A in different neurodegenerative diseases
New research spotlights UBE3A as more than the gene behind Angelman syndrome—revealing how its role across brain cells could unlock insights for AS, autism, Alzheimer’s, and other neurological conditions.
Exciting Announcement: Launch of Our New Electronic Journal
FAST has launched FAST-DART, a new open-access journal built to share every Angelman syndrome research finding, including negative results, so no discovery is lost, and progress toward treatments can move faster.
FAST Italy Hosts Its First Scientific Symposium on Angelman Syndrome
FAST Italy’s first-ever Scientific Symposium drew over 100 attendees and unveiled two new biotech companies, MavriX Bio and CourageAS Bio, advancing gene therapies for Angelman syndrome.